Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.
Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Articles by Suresh Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5